Bortezomib Isatuximab Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients

  • STATUS
    Recruiting
  • End date
    Dec 1, 2026
  • participants needed
    41
  • sponsor
    Medical College of Wisconsin
Updated on 21 November 2021
anemia
measurable disease
cell transplantation
bone marrow procedure
dexamethasone
bortezomib
hypercalcemia

Summary

This is a single-arm, open-label phase II study with a safety lead-in phase.

Description

The study hypothesis is that the isatuximab plus bortezomib, cyclophosphamide and dexamethasone (VCD) combination is safe and highly effective even in those with renal insufficiency (RI) from myeloma. In this study, we seek to improve the efficacy of VCD by adding isatuximab in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplant (ASCT) irrespective of renal function.

The primary objective is to determine if the addition of isatuximab to VCD will increase the proportion of subjects achieving very good partial response (VGPR), as defined by the International Myeloma Working Group (IMWG) criteria and by the time of completion of post-ASCT consolidation treatment.

Details
Condition Lymphoproliferative disorders, Lymphoproliferative Disorder, Multiple Myeloma, multiple myeloma (mm)
Treatment cyclophosphamide, Dexamethasone, Bortezomib, Isatuximab
Clinical Study IdentifierNCT04240054
SponsorMedical College of Wisconsin
Last Modified on21 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
Male or female subjects 18 years
Patients must be eligible for high-dose therapy and autologous stem cell transplantation as per institutional guidelines
No prior multiple myeloma (MM) -directed therapy except for dexamethasone (up to 160 mg), bortezomib (up to 5.2 mg/m2) and/or cyclophosphamide up to 500 mg/m2 administered for management of acute manifestations of MM (hypercalcemia, renal impairment, pain) for no longer than four weeks prior to enrollment. If subject received any prior therapy, pretreatment parameters necessary for disease characterization and response assessment (at least one of the following: Serum protein electrophoresis (SPEP)/Immunofixation electrophoresis (IFE), 24-hour urine protein with urine protein electrophoresis (UPEP)/ IFE, serum free light chains and bone marrow procedure) must be available
Patients must have documented multiple myeloma as defined by the criteria below (a, b, and c)
Monoclonal plasma cells in the bone marrow of 10% or presence of a biopsy proven plasmacytoma AND
Evidence of organ damage or myeloma-defining events (MDE) that can be attributed to the underlying proliferative plasma cell disorder (at least one of the following)
Hypercalcemia: serum calcium >1 mg/dL higher than the upper limit of normal
(ULN) or >11 mg/Dl
OR
Anemia: hemoglobin value of >2.0 g/dL below the lower limit of normal, or a
hemoglobin value <10.0 g/dL
OR
Bone marrow plasma cells of >60%. OR
Involved/uninvolved light chain ratio 100 OR
Renal insufficiency: creatinine clearance (CrCl) <40 mL/min (based on actual body weight; measured or estimated by validated equations and/or serum creatinine >177 mol/L (>2 mg/dL) [Only Cohort A subjects must meet this criterion] 3. Measurable disease as defined (at least one of the following)
Serum M-protein level 0.5 g/dL; OR
Urine M-protein level 200 mg/24 hours; OR
Light chain multiple myeloma without measurable disease in the urine: serum immunoglobulin (Ig) free light chains (FLC) 10 mg/dL and abnormal serum Ig kappa/lambda FLC ratio. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 7. Female subjects who
Are postmenopausal for at least one year before the screening visit, OR
Are surgically sterile, OR
Females of childbearing potential or male subjects with female partners of childbearing potential shall be required to use effective contraceptive methods (double barrier method, intrauterine device, oral contraception or abstinence) starting two weeks before first study drug(s) administration, while on therapy and for 16 weeks following the last dose of study drug(s). A woman is considered of childbearing potential, i.e., fertile, following menarche and until becoming postmenopausal unless permanently sterile. The following highly effective methods of contraception are accepted
Established use of oral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
Established use of oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
Placement of an intrauterine device or intrauterine hormone-releasing system
Barrier methods of contraception: male condom with either cap, diaphragm or sponge with spermicide (double-barrier methods). The use of double-barrier methods should always be supplemented with the use of a spermicide. Female condom and male condom should not be used together
Male sterilization (provided that the partner is the sole sexual partner of the patient and that the sterilized partner has received medical assessment of the surgical success)
Sexual abstinence
Female subjects must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction starting two weeks before first study drug(s) administration, while on therapy and for 16 weeks following the last dose of study drug(s). 8. Male subjects, even if surgically sterilized (i.e., status postvasectomy), who
Agree to practice effective barrier contraception during the entire study treatment period from the time of signing the informed consent through and through four months after the last dose of study drug(s) (female and male condoms should not be used together), or
Agree to practice true abstinence during the entire study treatment period from the time of signing the informed consent through 16 weeks after the last dose of study drug(s), when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)

Exclusion Criteria

Diagnosed or treated for malignancy other than multiple myeloma, except
Malignancy treated with curative intent and with no known active disease present for 3 years before enrollment
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
Adequately treated carcinoma in situ (e.g., cervical, breast) with no evidence of disease
Exhibiting clinical signs of or has a known history of meningeal or central nervous system involvement by multiple myeloma
Known to be seropositive for human immunodeficiency virus, known to have hepatitis B surface antigen positivity, or known to have untreated or active hepatitis C
Concurrent medical condition or disease (e.g., active systemic infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study. Specifically, any potential subject who is unsuitable for ASCT would be excluded from the study
Clinically significant cardiac disease, including
Myocardial infarction within six months before Cycle 1, Day 1, or unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV)
Uncontrolled cardiac arrhythmia (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] Version 5 Grade 2 or higher) or clinically significant electrocardiogram (ECG) abnormalities
Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >470 msec
Uncontrolled hypertension
Any of the following laboratory test results at the time of enrollment
Absolute neutrophil count <1.0 109/L; no granulocyte colony stimulating factor (G-CSF) treatment in the past seven days are allowed
Hemoglobin level 7.5 g/dL (5 mmol/L); blood transfusions to maintain hemoglobin >7.5 g/dL are acceptable
Platelet count <75 109/L for subjects in whom <50% of bone marrow nucleated cells are plasma cells; otherwise platelet count <50 109/L; no platelet transfusions in the past seven days are allowed
Alanine aminotransferase (ALT) level 2.5 ULN
Aspartate aminotransferase (AST) level 2.5 ULN
Total bilirubin level 1.5 ULN, (except for Gilbert Syndrome: direct bilirubin 2 ULN)
Known allergies, hypersensitivity (if not amenable to premedication with steroids, or H2 blockers), or intolerance to monoclonal antibodies or human proteins, isatuximab or its excipients or known sensitivity to mammalian-derived products
Plasma cell leukemia (>2.0 10^9/L circulating plasma cells by standard differential), Waldenstrm's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and/or skin changes), or light-chain amyloidosis
Known or suspected of not being able to comply with the study protocol (e.g., because of alcoholism, drug dependency, or psychological disorder) or the subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments
Pregnant or breastfeeding or planning to become pregnant starting two weeks before first study drug(s) administration, while on therapy and for 16 weeks following the last dose of study drug(s)
Plans to father a child starting two weeks before first study drug(s) administration, while on therapy and for 16 weeks following the last dose of study drug(s)
Had major surgery within two weeks before Cycle 1, Day 1, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study or within two weeks after the last dose of study drug administration. Note: Subjects with planned surgical procedures to be conducted under local anesthesia are not excluded. Kyphoplasty is not considered a major surgery
Patients with pre-existing uncontrolled pulmonary disease will be excluded; uncontrolled refers to patients having had at least one hospitalization due to pulmonary disease (for example, asthma, chronic obstructive pulmonary disease) within the six months prior to enrollment in the study; patients with previous history of pneumonitis will be excluded
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note